PHARMAC welcomes Myeloma NZ as first patient advocacy group to present to PTAC

21 November 2022 - Myeloma New Zealand presented directly to PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC) on Thursday, making ...

Read more →

Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body

20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years.  ...

Read more →

The patient voice – the value of patient-reported outcomes in HTA

4 August 2022 - The patient’s voice is increasingly important in securing access for therapies in markets and demonstrating how ...

Read more →

FDA official: patients play an increasing role in rare disease drug development

1 August 2022 - Patients have a critical role in drug development, from identifying unmet medical needs to assessing meaningful ...

Read more →

Pressured by patients, FDA reviews ALS drug with modest data

25 March 2022 - The FDA meets next week to review a closely watched drug for ALS, or Lou Gehrig’s ...

Read more →

Mentoring as a potential means to assist consumer representatives contribute effectively to the assessment of health technologies in Australia: a pragmatic review

7 February 2022 - This project was implemented on behalf of the Health Technology Assessment Consumer Consultative Committee to explore training ...

Read more →

Analysis of consumer comments into PBAC decision-making (2014–9)

4 February 2022 - Our objective was to analyse and review consumer comments in the PBAC's decision-making process. ...

Read more →

Bringing a consumer perspective to clinical advice

19 October 2021 - PHARMAC is making changes to the way its advisory committees work to strengthen the input of ...

Read more →

Consumers to have more say on medicine access issues

7 September 2021 - Consumer involvement in Australia’s medicines choices has been further strengthened under a new strategic agreement Medicines ...

Read more →

How to balance the patient voice atop the shifting plates of HTA

3 August 2021 - The tectonic plates of healthcare technology assessment have shifted – but where does the patient voice ...

Read more →

Patient advocacy organisations and FDA drug approval: lessons from Aduhelm

23 July 2021 - In the wake of last month’s controversial FDA approval of Biogen’s Aduhelm, Alzheimer’s Association CEO Harry ...

Read more →

How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations

15 July 2021 - Health technology assessment agencies vary in their use of quantitative patient preference data and the extent to ...

Read more →

MHRA outlines two year delivery plan with ‘patient first’ focus

6 July 2021 - The UK’s Medicines and Healthcare products Regulatory Agency has revealed its new delivery plan, outlining its ...

Read more →

ALS association wants more commitment from the FDA

24 June 2021 - In a response letter to the ALS Association, the U.S. FDA has recognised the unmet therapeutic ...

Read more →

Moving patient stories highlight opportunities to strengthen our health care systems for all Australians

24 June 2021 - It was an emotional evening among the nearly 200 in-person and online attendees at Parliament House last ...

Read more →